Keybank National Association OH Sells 564 Shares of argenex SE $ARGX

Keybank National Association OH decreased its stake in argenex SE (NASDAQ:ARGX) by 29.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,336 shares of the company’s stock after selling 564 shares during the quarter. Keybank National Association OH’s holdings in argenex were worth $976,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Abound Wealth Management boosted its stake in argenex by 3,200.0% during the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after acquiring an additional 32 shares during the last quarter. Sound Income Strategies LLC bought a new stake in argenex in the fourth quarter valued at approximately $28,000. Ameriflex Group Inc. acquired a new stake in argenex in the third quarter worth $32,000. Sunbelt Securities Inc. acquired a new stake in argenex in the third quarter worth $36,000. Finally, Aventura Private Wealth LLC bought a new position in shares of argenex during the fourth quarter worth $38,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Stock Performance

ARGX opened at $919.94 on Wednesday. argenex SE has a 52-week low of $536.02 and a 52-week high of $953.58. The firm has a market capitalization of $57.21 billion, a PE ratio of 40.96, a PEG ratio of 1.13 and a beta of 0.45. The business’s 50-day simple moving average is $846.35 and its 200 day simple moving average is $811.75.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The firm had revenue of $1.31 billion for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%. On average, research analysts forecast that argenex SE will post 26.27 earnings per share for the current year.

Wall Street Analyst Weigh In

ARGX has been the subject of a number of research analyst reports. Glj Research raised argenex to a “strong-buy” rating in a research note on Friday, April 3rd. Royal Bank Of Canada lifted their price objective on argenex from $890.00 to $945.00 and gave the company an “outperform” rating in a report on Tuesday. Weiss Ratings upgraded argenex from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday. HC Wainwright reissued a “buy” rating and set a $940.00 target price on shares of argenex in a research note on Thursday, June 25th. Finally, Oppenheimer dropped their target price on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, argenex presently has a consensus rating of “Moderate Buy” and an average price target of $1,037.61.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.